title: Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma.
abstract: OBJECTIVE
  To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC).
  
  
  METHODS
  Data were collected and analysed from 220 HCC patients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed.
  
  
  RESULTS
  Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child-Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence.
  
  
  CONCLUSIONS
  CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCC patients.
authors.affiliation: Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China.
authors.forename: T
authors.initials: T
authors.lastname: Yin
authors.affiliation: Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China.
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.affiliation: Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China.
authors.forename: P
authors.initials: P
authors.lastname: Zhao
authors.affiliation: Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China. Electronic address: zhengjiasheng6@sina.com.
authors.forename: J
authors.initials: J
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality* / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods / Q000401:mortality*; D002681:China / Q000453:epidemiology; D005260:Female; D006498:Hepatectomy / Q000379:methods / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality* / Q000601:surgery*; D008137:Longitudinal Studies; D008297:Male; D008872:Microwaves / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000401:mortality / Q000517:prevention & control; D015995:Prevalence; D012307:Risk Factors; D025321:Surgery, Computer-Assisted / Q000379:methods; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome